Hana Pharm Co., Ltd. (293480) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Hana Pharm Co., Ltd. (293480:KRX), powered by AI.

Current Price
₩9,260
P/E Ratio
18.7
Market Cap
164.6B
Sector
Healthcare
What is the Hana Pharm Co., Ltd. stock price forecast?

Hana Pharm Co., Ltd. is currently trading at ₩9,260. View real-time AI analysis on Alpha Lenz.

What is Hana Pharm Co., Ltd. insider trading activity?

View the latest insider trading data for Hana Pharm Co., Ltd. on Alpha Lenz.

What is Hana Pharm Co., Ltd.'s P/E ratio?

Hana Pharm Co., Ltd.'s P/E ratio is 18.7.

Hana Pharm Co., Ltd.

KRX · 293480
₩9,260-10(-0.11%)Market closedKRX regular session 09:00–15:30 KST
Ask about Hana Pharm Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Hana Pharm Co., Ltd. trades at a P/E of 18.7 (fair value) with modest ROE of 2.8%.

Ask for details

Company Overview

Hana Pharm Co., Ltd. is a dynamic pharmaceutical company primarily engaged in the research, development, production, and distribution of a broad range of medical products. Focused on addressing various therapeutic needs, the company offers products spanning sectors such as oncology, anesthetics, and cardiovascular treatments. Notably, Hana Pharm is recognized for its innovative drug delivery systems and cutting-edge formulation techniques, which enhance the efficacy and safety of its pharmaceutical offerings. Valued for its commitment to quality and innovation, Hana Pharm actively contributes to the healthcare industry's evolution by continually developing new treatment options and improving existing medications. The market significance of Hana Pharm can be attributed to its strategic investments in research and development, which not only bolster its product pipeline but also reinforce its competitive edge in the pharmaceutical market. Additionally, its range of products caters to diverse healthcare markets, both domestically and internationally, helping improve patient outcomes and accessibility to advanced medications.

CEO최태홍
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

FY 2025

Profile

₩164,577,479,960Market Cap
₩239,503,892,650Revenue
17.77MShares Out
0Employees

Margins

60.48%Gross
16.28%EBITDA
10.78%Operating
7.67%Pre-Tax
3.67%Net

Valuation

18.75P/E
0.53P/B
0.69EV/Sales
5.47EV/EBITDA
-7.48P/FCF

Growth (CAGR)

4.34%Rev 3Yr
6.20%Rev 5Yr
-6.09%Op Inc 3Yr
-4.01%Op Inc 5Yr
-28.79%Net Inc 3Yr
-10.03%Net Inc 5Yr

Returns

2.19%ROA
2.82%ROE
6.45%ROIC

Financial Health

₩9,841,089,300Cash & Cash Equivalents
₩94,890,855,050Net Debt
33.42%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Hana Pharm Co., Ltd. (ticker: 293480) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $164.6B.

The current price is ₩9,260 with a P/E ratio of 18.75x and P/B of 0.53x.

ROE is 2.82% and operating margin is 10.78%. Annual revenue is $239.5B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Hana Pharm Co., Ltd. (293480) Stock Forecast 2026 ₩9,260 — Price, Financials & Analyst Targets | Alpha Lenz